Gedeon Richter releases updated product documentation for Lindinet 30

Gedeon Richter has released updated clinical documentation regarding Lindinet 30, a combined hormonal oral contraceptive containing gestodene and ethinylestradiol. The medication is formulated to prevent pregnancy by inhibiting ovulation and altering the cervical environment.

The updated documentation highlights the necessity of a medical evaluation prior to use, specifically addressing potential risks such as venous and arterial thrombosis. Patients are advised to disclose their full medical and family history to their physicians to determine if the contraceptive is appropriate for their individual health profile.

The guidelines delineate strict contraindications, prohibiting use in patients with histories of severe liver disease, clotting disorders, or uncontrolled hypertension. It is noted that the medication does not offer protection against sexually transmitted infections or HIV.